Home › Core › ISCC-IDs › 28CrXNbwMRxeb

View ISCC-ID

Core Data

28CrXNbwMRxeb
ISCC-ID - digital asset identifier
CCXS8ueXbGbVE-CTjCbwmGgRqF6-CDg2mHqr197Pq-CRmUD96YGqx4H
ISCC-CODE - digital asset descriptor
2QTa5N4aeSrCB2MLoPdPF4AsTjstJgcLTnd
PUBLIC-KEY or WALLET-ADDRESS of DECLARING PARTY
0
Number of times updated

Seed Metadata (Immutable)

what advances have been made in immunetherapy for renal cell carcinoma

Ledger Reference

coblo
Source Ledger/Blockchain
541198
N-th ISCC Decleration on source ledger
263b6138b380a51c2c859f0bddf6021b6d2afa3afeade0538db1bcfa41b91b55
Hash of block that includes the ISCC-DECLARATION
8b07704436714dbfdcfd8a7c40276134253411f95421e1f5ed910c3681242597
Hash of transaction that includes the ISCC-DECLERATION
0
Output index that includes ISCC-DECLERATION (UTXO based chains)

Mutable Metadata

[{"data": {"name": "What advances have been made in immune-therapy for renal cell carcinoma?", "@type": "ScholarlyArticle", "genre": "journal-article", "author": [{"name": "Elena Verzoni", "@type": "Person"}, {"name": "Paolo Grassi", "@type": "Person"}, {"name": "Raffaele Ratta", "@type": "Person"}], "@context": "http://schema.org/", "encoding": [{"@type": "MediaObject", "contentUrl": "https://www.futuremedicine.com/doi/pdf/10.2217/fon-2017-0026", "encodingFormat": "application/pdf"}], "publisher": {"name": "Future Medicine Ltd", "@type": "Organization"}, "identifier": [{"@type": "PropertyValue", "value": "10.2217/fon-2017-0026", "propertyID": "DOI"}, {"@type": "PropertyValue", "value": "CCXS8ueXbGbVE-CTjCbwmGgRqF6-CDg2mHqr197Pq-CRmUD96YGqx4H", "propertyID": "ISCC"}], "datePublished": "2017-04-01"}, "schema": "schema.org", "mediatype": "application/ld+json"}]
Close